Patents Issued in December 11, 2007
  • Composition for thick oxide superconductor film and method of producing oxide superconductor in form of thick film tape using the same
    Patent number: 7307046
    Abstract: To provide a composition for a thick oxide superconducting film containing a copper salt of a branched saturated aliphatic carboxylic acid having 6 or more carbon atoms and/or a copper salt of an alicyclic carboxylic acid having 6 or more carbon atoms, which is suitable for producing thick copper based oxide superconducting films by the MOD process and which can be subjected to film formation with uniformity at a high speed, and an oxide superconductor in the form of a thick film tape which is subjected to film formation with uniformity at a high speed using the subject composition for a thick oxide superconducting film.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: December 11, 2007
    Assignees: International Superconductivity Technology Center, The Juridical Foundation, Adeka Corporation, SWCC Showa Cable Systems Co., Ltd.
    Inventors: Honjo Tetsuji, Tokunaga Yoshitaka, Izumi Teruo, Shiohara Yuh, Goto Tomotaka, Yoshinaka Atsuya, Yajima Akimasa
  • Lepidocrocite potassium magnesium titanate, method for manufacturing the same and friction material
    Patent number: 7307047
    Abstract: Lepidocrocite potassium magnesium titanate having a composition represented by the formula K0.2-0.7Mg0.4Ti1.6O3.7-4 and obtainable by subjecting an aqueous slurry of lepidocrocite potassium magnesium titanate having a composition represented by the formula K0.8Mg0.4Ti1.6O4 to an acid treatment and subsequent calcination.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: December 11, 2007
    Assignee: Otsuka Chemical Co., Ltd.
    Inventors: Hiroshi Ogawa, Shigeo Takahashi, Nobuki Itoi, Kousuke Inada
  • Transmission oil composition for automobile
    Patent number: 7307048
    Abstract: A transmission oil composition for an automobile characterized in that it contains a base oil selected from the group consisting of a mineral oil, a synthetic oil and mixtures thereof; and a phosphate compound selected from the group consisting of (A) a zinc dithiophosphate having a hydrocarbon group, (B) a triaryl phosphate (C) a triaryl thiophosphate, and mixtures thereof at 0.1 to 15.0% by mass with respect to the total composition; wherein the composition has a volume resistivity of 1×107 ohm·m or more at 80° C.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: December 11, 2007
    Assignees: Nissan Motor Co., Ltd., Nippon Oil Corporation
    Inventors: Takumaru Sagawa, Takafumi Ueno, Hisayuki Wada, Tooru Aoki
  • Antioxidants for synthetic lubricants and methods and manufacture
    Patent number: 7307049
    Abstract: Provided are compounds of formula wherein R1 is linear or branched alkyl; AR is phenyl, naphthyl, or phenanthryl; and m is 0, 1, or 2; and R2 is an alkyl substituted carboxyl. Lubricating oils comprising a polyol ester lubricant in combination with one or more compounds of Formula I are also provided. Compounds having structures of Formula I are formed by mixing N-4-alkylphenyl-1-naphthylamine, paraformaldehyde, glacial acetic acid, and a polyol ester base lubricant and heating and stirring the mixture to cause a condensation reaction. Water and acetic acid are subsequently removed, thereby providing the compound of formula I in the polyol ester base lubricant.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: December 11, 2007
    Assignee: Anderol, Inc.
    Inventor: Eugene P. DiBella
  • Aqueous hair cleansing composition comprising a sulfate surfactant mixture and an amino-modified silicone
    Patent number: 7307050
    Abstract: An aqueous hair cleansing composition made up of a sulfate surfactant, at least one amino-modified silicone and/or at least one water soluble cationic polymer, and a silicon oil.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: December 11, 2007
    Assignee: Kao Corporation
    Inventor: Eiji Terada
  • Color changing hand soap composition
    Patent number: 7307051
    Abstract: A composition can indicate whether hands have been washed for an approximate predetermined period of time. The composition includes a pH indicator and a delivery system. The delivery system contains a pH-altering compound. The delivery system is added to the pH indicator approximately when hand washing begins. A method of washing hands is also presented. The pH indicator is applied to the hands. The delivery system is applied to the hands approximately when hand washing begins. The pH indicator and delivery system are mixed. A system for washing hands is also presented. The system includes a pH indicator, a delivery system, and a dispenser that releases the pH indicator and delivery system to hands. The hands are washed until the pH indicator changes color.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: December 11, 2007
    Inventor: Sarah Rich
  • Cleaning composition with improved dispensing and cling
    Patent number: 7307052
    Abstract: A thickened oxidant composition is formulated to be easily and evenly applied to a vertical surface to provide consumer preferred cling to the vertical surface. The composition has a low relaxation constant. The composition is useful in cleaning toilet bowls and other hard surfaces. The composition can be applied in a stream, a spray, or an aerosol.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: December 11, 2007
    Assignee: The Clorox Company
    Inventors: Geetha Murthy, Daniela Fritter, Robert J. Iliff, Paula Ann Sanchez
  • Combination air sanitizer, soft surface deodorizer/sanitizer and hard surface disinfectant
    Patent number: 7307053
    Abstract: An improved combination air sanitizer, soft surface sanitizer, soft surface deodorizer and hard surface disinfectant is disclosed. The preferred active ingredient for the air sanitization and soft surface odor treatment functions is triethylene glycol (TEG). The preferred active ingredient for soft surface sanitization and hard surface disinfection functions is a mixture of various alkyl dimethyl benzyl ammonium saccharinates. The formulation may be provided in an aerosol spray form and is useful for sanitizing and removing bacteria and malodorant molecules from the air as well as disinfecting hard surfaces. A unique combination of corrosion inhibitors is disclosed for convention steel or tin-plated steel cans. A single produce can be used as an air sanitizer/air freshener, a soft surface sanitizer, a soft-surface odor remover/reducer and, a hard surface disinfectant.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 11, 2007
    Assignee: S.C. Johnson & Son, Inc.
    Inventors: Maciej K. Tasz, George J. Svoboda
  • Vapor compression air conditioning or refrigeration system cleaning compositions and methods
    Patent number: 7307054
    Abstract: The present invention relates to compositions that are suitable for removing or reducing residue from a vapor compression air conditioning or refrigeration system consisting essentially of 1,1,1,2,2,3,4,5,5,5-decafluoropentane and polyol ester, and methods of using the composition.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: December 11, 2007
    Assignee: E.I. du Pont de Nemours and Company
    Inventor: David J. Bateman
  • Cleaning implements
    Patent number: 7307055
    Abstract: Disclosed herein is a cleaning article as an article of manufacture which includes a substrate onto which a cleaning composition is partially impregnated, leaving a portion of the substrate not impregnated with the composition. The impregnated part or side of the substrate is used to clean surfaces, especially vitro-ceramic surfaces while the unimpregnated part or side of the substrate is then used to dry and buff the cleaned surface.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: December 11, 2007
    Assignee: Reckitt Benckiser Inc.
    Inventors: Andrew David Cook, Edward Mathew Cooney, Michael Vincent Monticello
  • Disinfecting peroxosilicated compound with scale preventive effect, preparation method and use thereof
    Patent number: 7307056
    Abstract: The invention concerns a peroxosilicated, optionally phosphatized, disinfecting compound with scale preventive effect obtained by reacting an alkaline or alkaline-earth metasilicate with an active oxygen-releasing compound, for example potassium monopersulphate and/or oxygen peroxide, in inert medium. The compound can be stabilized with sodium hexametaphosphate. Copper and aluminium in salt form can be encapsulated or complexed with the metasilicate so that the resulting peroxosilicated compound can be used for its disinfecting, scale preventive, anticorrosive, flocculating and algicidal properties for more than three weeks.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: December 11, 2007
    Assignee: EOTEC
    Inventors: Morou Boukari, Marc Auriol, Sophie Auriol
  • Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
    Patent number: 7307057
    Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: December 11, 2007
    Assignee: Naicons S.C.A.R.L.
    Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
  • Multimeric Apo A-I agonist compounds
    Patent number: 7307058
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: December 11, 2007
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water
    Patent number: 7307059
    Abstract: Provided herein are methods for measuring protein biosynthesis by using 2H2O or radioactive 3H2O and applicable uses thereof.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: December 11, 2007
    Assignee: The Regents of the University of California
    Inventor: Marc K. Hellerstein
  • Hypoxia inducible factor 2? for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
    Patent number: 7307060
    Abstract: The current invention relates to the field of hypoxia-induced disorders and more specifically to the use of hypoxia inducible factor 2? as a target in a method for the screening for molecules that can be used for the treatment of pulmonary hypertension. The invention further relates to the use of HIF-2? and/or of the HIF-2? inducible protein VEGF for the treatment of neonatal respiratory distress syndrome.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: December 11, 2007
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Veerle Compernolle, Peter Carmeliet
  • ?-peptoids with antimicrobial activity
    Patent number: 7307061
    Abstract: The present invention relates to beta-peptoids with antimicrobial activity. The present invention also relates to methods of producing ?-peptoids. The antimicrobial ?-peptoids of the invention are useful in pharmaceutical, healthcare, medical device, industrial, food, agricultural, and personal care applications.
    Type: Grant
    Filed: December 19, 2005
    Date of Patent: December 11, 2007
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Steven W. Shuey, William J. Delaney, Mukesh C. Shah, Mark A. Scialdone
  • Method for treating a mental disorder
    Patent number: 7307062
    Abstract: A method of treating an individual exhibiting at least one symptom of a mental disorder is provided which comprises administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder. This invention also pertains to a method of treating an individual exhibiting at least one symptom of a mental disorder by administering a probiotic mixture to replenish gastrointestinal microbes.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: December 11, 2007
    Inventor: Ellen R. Bolte
  • Melanocortin metallopeptides for treatment of sexual dysfunction
    Patent number: 7307063
    Abstract: Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: December 11, 2007
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh Sharma, Annette Shadiack, Yi-Qun Shi, Wei Yang, Hui-Zhi Cai
  • Methods for treating cardiovascular disease using a soluble CTLA4 molecule
    Patent number: 7307064
    Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: December 11, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: James Rusnak
  • 2?-Fluoronucleosides
    Patent number: 7307065
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: December 11, 2007
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
    Patent number: 7307066
    Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: December 11, 2007
    Assignee: Tripep AB
    Inventor: Matti Sallberg
  • Methods and compositions for reducing viral genome amounts in a target cell
    Patent number: 7307067
    Abstract: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: December 11, 2007
    Assignee: The Board of Trustees of the Leland Stanford University
    Inventors: Peter Sarnow, Catherine L. Jopling, Alissa M. Lancaster
  • Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
    Patent number: 7307068
    Abstract: Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 11, 2007
    Assignee: Genzyme Corporation
    Inventor: Abraham Scaria
  • Antisense oligonucleotide modulation of STAT3 expression
    Patent number: 7307069
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: December 11, 2007
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: James G. Karras
  • Microbicidal compositions
    Patent number: 7307070
    Abstract: There are described the use of ?-(4-chlorophenyl)-?-(1-cyclopropylethyl)-1H-1,2,4-triazole-1-ethanol as a microbicide for the protection of industrial materials, and compositions containing this compound.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: December 11, 2007
    Assignee: Lanxess Deutschland GmbH
    Inventors: Lutz Heuer, Peter Wachtler, Michael Schwamborn, Martin Kugler, Hans-Ulrich Buschhaus
  • RAF-MEK-ERK pathway inhibitors to treat cancer
    Patent number: 7307071
    Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: December 11, 2007
    Assignee: Onyx Pharmaceuticals, Inc
    Inventors: John F. Lyons, Gideon Bollag
  • Oral pharmaceutical suspension of Cefdinir crystal
    Patent number: 7307072
    Abstract: The present invention relates to a novel oral pharmaceutical suspension of Cefdinir crystal. More specifically, the present invention relates to a novel kit for preparation of an oral pharmaceutical suspension containing crystal form C Cefdinir.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: December 11, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Naozumi Ohnishi, Shuhei Deguchi, Satoshi Kitamura
  • Benzoxazepines derivatives and their use as AMPA receptor stimulators
    Patent number: 7307073
    Abstract: The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or SO2; R1, R2, R3 and R4 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, halogen, nitro, cyano, NR8R9, NR8COR10, and CONR8R9, R5, R6 and R7 are independently H or (C1-4)alkyl; R8 and R9 are independently H or (C1-4)alkyl; or R8 and R9 form together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR11; R10 is (C1-4)alkyl; R11 is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: December 11, 2007
    Assignee: N.V. Organon
    Inventors: Simon James Anthony Grove, Mingqiang Zhang, Mohammad Shahid
  • Diazepan derivatives or salts thereof
    Patent number: 7307074
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4?-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: December 11, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe
  • Tetrahydroquinoline analogues as muscarinic agonists
    Patent number: 7307075
    Abstract: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: December 11, 2007
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Niels Skjaerbaek, Kristian Norup Koch, Bo Lennart Mikael Friberg, Bo-Ragnar Tolf
  • Beta agonists for the treatment of respiratory diseases
    Patent number: 7307076
    Abstract: The present invention relates to compounds of general formula 1 wherein the groups n, A, B, R1, R2 and R3 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: December 11, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ingo Konetzki, Thierry Bouyssou, Philipp Lustenberger, Andreas Schnapp, Marco Santagostino, Christoph Hoenke
  • Heterocyclic compound and antitumor agent containing the same as effective ingredient
    Patent number: 7307077
    Abstract: The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1-C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1-C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl), oxazolidinyl (which may be substituted with one or two C1-C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1-C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.
    Type: Grant
    Filed: July 3, 2006
    Date of Patent: December 11, 2007
    Assignee: Zenyaku Kogyo Kabushiki Kaisha
    Inventors: Seiichiro Kawashima, Toshiyuki Matsuno, Shinichi Yaguchi, Hiroya Sasahara, Tetsuo Watanabe
  • Polycyclic compounds which modulate PPAR? type receptors and cosmetic/pharmaceutical compositions comprised thereof
    Patent number: 7307078
    Abstract: Novel polycyclic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: December 11, 2007
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Pascal Collette, Michel Rivier, Andre Jomard
  • 1,3,5-Triazine derivatives as ligands for human adenosine-A3 receptors
    Patent number: 7307079
    Abstract: The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient. The invention relates to compounds of the general formula (1) wherein Y represents a group of the general formula (A), (B) or (C) and all other symbols have the meanings as given in the description.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: December 11, 2007
    Assignees: Solvay Pharmaceuticals, B.V., Arqule, Inc.
    Inventors: Jacobus A.J. Den Hartog, Jan H. Reinders, Guustaaf J.M. Van Scharrenburg, Maria L. Pras-Raves, Gary R. Gustafson
  • Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
    Patent number: 7307080
    Abstract: The disclosure relates to compounds, pharmaceutical compositions and methods for inhibiting PARP by use of the disclosed compositions.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: December 11, 2007
    Assignee: MGI GP, Inc.
    Inventors: Jia-He Li, Jie Zhang
  • Piperidine derivatives useful as CCR5 antagonists
    Patent number: 7307081
    Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: December 11, 2007
    Assignee: Schering Corporation
    Inventors: Michael W. Miller, Jack D. Scott
  • Heterocyclic derivatives as CRF antagonists
    Patent number: 7307082
    Abstract: This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I wherein X1 is (CH2)n or CO, n is 0 to 2 and R1, R2, R3 and R4 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: December 11, 2007
    Assignee: Roche Palo Alto LLC
    Inventors: Counde O'Yang, Ryan Craig Schoenfeld
  • Tetrahydro-acridine and dithiolane derivatives
    Patent number: 7307083
    Abstract: Compounds identified by the general formula (I) are used for the treatment of Alzheimer's disease
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: December 11, 2007
    Assignee: Alma Mater Studiorum-Universita'di Bologna
    Inventors: Michela Rosini, Vincenza Andrisano, Manuela Bartolini, Carlo Melchiorre
  • Cyclic benzimidazoles
    Patent number: 7307084
    Abstract: The invention relates to cyclic benzimidazoles of formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: December 11, 2007
    Assignee: Altana Pharma AG
    Inventors: Wilm Buhr, M. Vittoria Chiesa, Peter Jan Zimmermann
  • Mitotic kinesin inhibitors
    Patent number: 7307085
    Abstract: The present invention relates to bicyclic tetrahydropyridine compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: December 11, 2007
    Assignee: Merck & Co., Inc.
    Inventor: Paul J. Coleman
  • 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
    Patent number: 7307086
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: December 11, 2007
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Changsheng Zheng, Ganfeng Cao, Hao Feng, Michael Xia, Rajan Anand, Joseph Glenn, Brian W. Metcalf
  • Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
    Patent number: 7307087
    Abstract: This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: December 11, 2007
    Assignee: Neurosearch A/S
    Inventors: Gunnar M. Olsen, Dan Peters, Elsebet Østergaard Nielsen
  • Substituted anthranilic amide derivatives and methods of use
    Patent number: 7307088
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: December 11, 2007
    Assignee: Amgen Inc.
    Inventors: Qi Huang, Guoqing Chen, Aiwen Li, Babak Riahi, Andrew Tasker, Kevin Yang, Chester Chenguang Yuan
  • Aryloxy quinolines and uses thereof
    Patent number: 7307089
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein m, Ar, R1, R2, and R3 are as defined herein. The invention also provides methods for preparing, coompositions comprising, and methods for using compounds of Formula 1 for treatment of central nervous system disorders.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: December 11, 2007
    Assignee: Roche Palo Alto LLC
    Inventors: Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Piperidine derivatives useful as modulators of chemokine receptor activity
    Patent number: 7307090
    Abstract: The invention provides a compound of formula (I), wherein: T is C(O) or S(O)2; W is C(O) or S(O)2; X is CH2, O or NH; Y is CR5 or N; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2 is hydrogen or C1-6alkyl; R3 is hydrogen or optionally substituted C1-6alkyl; and R4 is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: December 11, 2007
    Assignee: AstraZeneca AB
    Inventors: Richard Evans, Matthew Perry, Brian Springthorpe
  • Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
    Patent number: 7307091
    Abstract: The invention discloses deuterated 3-piperidinopropiophenones as well as their physiologically tolerated salts. Furthermore, the invention concerns the use of deuterated 3-piperidinopropiophenones for the treatment of muscular illnesses as well as for the preparation of pharmaceutical drugs for the treatment of muscular illnesses. In addition, the invention discloses pharmaceutical formulations containing deuterated 3-piperidinopropiophenones as well as their physiologically tolerated salts for the treatment of muscular illnesses in addition to containing pharmaceutically tolerated adjuvants and/or additives.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: December 11, 2007
    Assignee: BDD Berolina Drug Development GmbH
    Inventors: Rudolf-Gisbert Alken, Thomas Stabingis
  • Compounds Capable of Activating Cholinergic Receptors
    Patent number: 7307092
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: December 11, 2007
    Assignee: Targacept, Inc.
    Inventors: William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared Miller Wagner, Peter Anthony Crooks
  • Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
    Patent number: 7307093
    Abstract: Substituted thiazolidinone carboxylic acid amides and substituted thiazolidine carboxylic acid amides according to formulae (I) and (II) are disclosed where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: December 11, 2007
    Assignees: The University of Tennessee Research Foundation, Ohio State University Research Foundation
    Inventors: Duane D. Miller, Veeresa Gududuru, James T. Dalton, Eunju Hurh
  • Benzoxazole carboxamides for treating CINV and IBS-D
    Patent number: 7307094
    Abstract: Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: December 11, 2007
    Assignee: AMR Technology, Inc.
    Inventors: David J. Fairfax, Zhicai Yang
  • Inhibitors of cathepsin S
    Patent number: 7307095
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: December 11, 2007
    Assignee: IRM LLC
    Inventors: Hong Liu, David Tully, Phillip Alper, Robert Epple, Arnab Chatterjee, Michael Roberts